24,99 €
inkl. MwSt.
Versandfertig in über 4 Wochen
12 °P sammeln
Andere Kunden interessierten sich auch für
![Design and Synthesis of New Thiazole Derivatives as Anticancer Agents]( "Design and Synthesis of New Thiazole Derivatives as Anticancer Agents")
Design and Synthesis of New Thiazole Derivatives as Anticancer Agents40,99 €![Synthesis of Novel Coupled Nitrogen Heterocyclic Compounds]( "Synthesis of Novel Coupled Nitrogen Heterocyclic Compounds")
Synthesis of Novel Coupled Nitrogen Heterocyclic Compounds26,99 €![Quinazolinone derivatives as anti-microbial agents]( "Quinazolinone derivatives as anti-microbial agents")
Quinazolinone derivatives as anti-microbial agents32,99 €![Design, Synthesis and Evaluation of Some Novel Heterocyclic Compounds]( "Design, Synthesis and Evaluation of Some Novel Heterocyclic Compounds")
Design, Synthesis and Evaluation of Some Novel Heterocyclic Compounds26,99 €![Biological Prospective of Heterocyclic Compounds]( "Biological Prospective of Heterocyclic Compounds")
Biological Prospective of Heterocyclic Compounds32,99 €![Biological Importance of Heterocyclic Compounds in future]( "Biological Importance of Heterocyclic Compounds in future")
Biological Importance of Heterocyclic Compounds in future46,99 €![Standardization and Fingerprinting of Polyherbal Bioactive Compounds]( "Standardization and Fingerprinting of Polyherbal Bioactive Compounds")
Standardization and Fingerprinting of Polyherbal Bioactive Compounds46,99 €
Some new amino substituted quinazoline compounds were synthesized and evaluated for their anticancer activity at National Cancer Institute (NCI), U.S.A. Among the synthesized nine compounds, two were selected for single high dose screening (10-5 M) in full 60 cell panel. Among the selected compounds, 2-benzamido-N-(benzo[d]thiazol-2-yl)benzamide 4 exhibited significant anticancer activity against non-small cell lung cancer NCI-H23, colon cancer HCT-15, CNS cancer SF-539, melanoma SK-MEL-5, ovarian cancer OVCAR-8, renal cancer ACHN, prostate cancer PC-3 and breast cancer MCF7 with inhibition rate of 97.82%, 99.67%, 99.21%, 90.75%, 99.21%, 99.31%, 97.23% and 93.29% respectively. This compound was selected for testing under five dose level screening against 60 cancer cell lines. The results of five dose assay revealed significant anticancer activity of this compound against almost all cancer cell lines.